key: cord-0931203-2unkdr26 authors: Yalçın, Tuğba Y.; Topçu, Deniz İ.; Doğan, Özlem; Aydın, Saliha; Sarı, Nuran; Erol, Çiğdem; Kuloğlu, Zeynep E.; Azap, Özlem K.; Can, Füsun; Arslan, Hande title: Immunogenicity after two doses of inactivated virus vaccine in healthcare workers with and without previous COVID‐19 infection: Prospective observational study date: 2021-09-10 journal: J Med Virol DOI: 10.1002/jmv.27316 sha: ef08bc35898e4088db81100fefef210d18e77d9b doc_id: 931203 cord_uid: 2unkdr26 Vaccines have been seen as the most important solution for ending the coronavirus disease 2019 (COVID‐19) pandemic. The aim of this study is to evaluate the antibody levels after inactivated virus vaccination. We included 148 healthcare workers (74 with prior COVID‐19 infection and 74 with not). They received two doses of inactivated virus vaccine (CoronaVac). Serum samples were prospectively collected three times (Days 0, 28, 56). We measured SARS‐CoV‐2 IgGsp antibodies quantitatively and neutralizing antibodies. After the first dose, antibody responses did not develop in 64.8% of the participants without prior COVID‐19 infection. All participants had developed antibody responses after the second dose. We observed that IgGsp antibody titers elicited by a single vaccine dose in participants with prior COVID‐19 infection were higher than after two doses of vaccine in participants without prior infection (geometric mean titer: 898 and 607 AU/ml). IgGsp antibodies, participants with prior COVID‐19 infection had higher antibody levels as geometric mean titers at all time points (p < 0.001). We also found a positive correlation between IgGsp antibody titers and neutralizing capacity (r (s) = 0.697, p < 0.001). Although people without prior COVID‐19 infection should complete their vaccination protocol, the adequacy of a single dose of vaccine is still in question for individuals with prior COVID‐19. New methods are needed to measure the duration of protection of vaccines and their effectiveness against variants as the world is vaccinated. We believe quantitative IgGsp values may reflect the neutralization capacity of some vaccines. have previously been infected with COVID-19. [2] [3] [4] CoronoVac is an inactivated virus vaccine developed by Sinovac Life Sciences in early 2020. After demonstrating the safety and efficacy of the vaccine in Phase 1/2 studies, 5, 6 Phase 3 studies were initiated in Brazil, Indonesia, Chile, and Turkey. CoronaVac efficacy was found to be 83.5% in the Phase 3 study in Turkey. 7 In an April 2021 report, the World Health Organization (WHO) stated that the CoronaVac vaccine is effective in preventing COVID-19, and they approved it for emergency use in June 2021. 8, 9 Individuals and clinicians are trying to understand the effectiveness of vaccines and how long the protection lasts as vaccination rates rise. Assessments of vaccine effectiveness are based on realworld data that takes time. In vaccination research with influenza, smallpox, and polio, it has been stated that the neutralizing antibody response predicts vaccine protection, and it is known to play an important role in severe acute respiratory syndrome coronavirus 2. 10 However, neutralizing antibody tests are not widely used because of technical and financial issues. Vaccines induce an immune response against viral spike protein. Anti-spike antibodies are produced by the immune system and may serve as an indicator of protection. 11 The first goal of this study is to follow up the serological responses to the inactivated virus vaccine, namely CoronaVac, among healthcare workers (HCWs) who had or did not have past COVID-19. The secondary goal is to investigate the impact of the level of quantitative antibody on neutralization capacity. Inclusion criteria for participants with prior COVID-19 infection were SARS-CoV-2 polymerase chain reaction (PCR) positivity in the preceding months, as well as contact and symptomatic disease in any period before vaccination. Participants who had not previously been infected with COVID-19 were eligible if they had not SARS-CoV-2 PCR positivity, no history of quarantine, no history of therapy against COVID-19 and SARS-CoV-2 IgGsp levels <50 AU/ml in their serum before vaccination. Antibody levels were measured just before the first dose (Day 0), just before the second dose (Day 28), and 28 days after the second dose (Day 56). Serological testing for antibodies to the receptor of the S1 subunit of the viral spike protein (IgGsp) was performed with the Abbott Architect SARS-CoV-2 IgG Quant II (Abbott). Neutralizing antibodies from 31 participants were tested. This After incubation, supernatants were discarded and cells were supplemented with DMEM and 2% methylcellulose solution. After 4 days at 37°C, supernatants were removed and the six-well plates were fixed and inactivated using 4% paraformaldehyde and stained with crystal violet. Serum dilutions with a PRNT of 50% (PRNT50) are referred to as titers. Unless stated otherwise, cut-off titers were set at <1:20. A standardized questionnaire asking about the demographic characteristics of the participants-age, gender, socioeconomic status, marital status, comorbidity, smoking, and alcohol use-and the use of paracetamol and/or nonsteroidal anti-inflammatory drugs (NSAIDs) was filled out by all participants with the guidance of an infectious diseases specialist. Socioeconomic status was determined using the income and expenditure self-report. The use of paracetamol and/or NSAIDs was defined for both chronic use and 24 h before and after vaccination. To evaluate the body mass index (BMI) of participants, their heights and weights were measured on a standard scale using a measuring instrument. The Pittsburgh sleep quality index (PSQI) was applied to assess sleep states, and those with PSQI ≥ 5 were classified as having poor quality sleep. The disease severity of the previously infected participants was categorized into three groups according to WHO classification: mild, moderate, and severe. 13 In any of the participants during follow-up, there was no symptomatic disease, though this is based on the participants' self-reports, as SARS-CoV-2 PCR tests were not administered. The design of this study was followed using the Strengthening the Reporting of Observational Studies in Epidemiology checklist. This study was approved by the Baskent University Institutional Review Board and Ethics Committee (Project no: KA21/51) and was supported by the Baskent University Research Fund. Antibody levels were presented as GMTs and confidence intervals. Antibody levels were converted to base 10 logarithms and used in statistical analysis for intergroup comparison. By testing the compatibility of numerical data to a normal distribution, parametric data were evaluated using Student's t tests in paired comparison and Mann-Whitney U tests for those who did not have parametric properties. Analysis of the nominal data χ 2 test or Fisher's exact test was used. When changes of numerical variables were obtained with more than two measurements in a single group, the Friedman test was used if the variables were not normally distributed, and analysis of variance was used for repeated measures. Spearman's correlation coefficient was used to measure the strength of association between antibody levels and neutralized antibody results. Statistical analysis was done with IBM ® SPSS© 25 software. Situations below 5% of the type 1 error level were interpreted as statistically significant. Of the 148 HCW participants included in the study, 104 (70.3%) were women, and the median age was 39 years (min 22-max 64). Forty-five of the participants (30.4%) had comorbidity; the most prevalent being thyroid dysfunction (13/148, 8.8%). This was followed by hypertension (11/148, 7.4%) and rheumatic disease (10/148, 6.8%). The demographic characteristics of the participants are given in Table S1 . The serological response to the vaccine, natural immune response, and correlation with IgGsp antibody titers was evaluated. Sera from 31 participants were evaluated by neutralization assays and a response equal to or greater than 1/160 dilution was detected (IgGsp antibody titers ranged from 70 to 1526 AU/ml). Neutralizing antibody responses without vaccine were detected 1/320 dilution for those who had past COVID-19 infection and the lowest antibody titers. However, the lowest antibody titers in second-dose vaccinated participants who had not been previously infected with COVID-19 had 1/160 dilution of neutralizing capacity (Figure 4 ). We found a positive correlation between IgGsp antibody titers and neutralizing capacity- CoronaVac has been shown to be effective in preventing symptomatic or severe illness. 7 It was also found to be effective According to current evidence, the natural immune response can last up to 9 months after COVID-19 infection. 18 We also demon- It is well known that not only spike antibodies but also T-and B-cell timing. This is a pioneering study, and more comprehensive research on the subject is required. The authors declare that there are no conflict of interests. The data that support the findings of this study are available on request from the corresponding author (Dr. Tuğba Y. Yalçın). The data are not publicly available due to patient privacy. REFERENCES 1. WHO Health Emergency Dashboard.WHO (COVID-19). Homepage; 2021. Accessed Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine Binding and neutralization antibody titers after a single vaccine dose in health care workers previously infected with SARS-CoV-2 Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2 Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebocontrolled, phase 1/2 clinical trial Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey For recommendatıon by the Strategıc Advısory Group of Experts (Sage) on Immunızatıon. Prepared by the SAGE Working Group on COVID-19 vaccines; 2021. Accessed World Health Organization.WHO validates Sinovac COVID-19 vaccine for emergency use and issues interim policy recommendations Commercial serology assays predict neutralization activity against SARS-CoV-2 Quantitative SARS-CoV-2 antispike responses to Pfizer-BioNTech and Oxford-AstraZeneca vaccines by previous infection status Public attention; 2021 COVID-19 clinical management: living guidance; 2021. Accessed SARS-CoV-2 IgG II Quant Assay User Manual Serum neutralising activity against SARS-CoV-2 variants elicited by CoronaVac Susceptibility of circulating SARS-CoV-2 variants to neutralization Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection SARS-CoV-2 antibody dynamics and B-cell memory response over time in COVID-19 convalescent subjects SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN) Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection Disease severity dictates SARS-CoV-2-specific neutralizing antibody responses in COVID-19 A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity Kinetics of viral load and antibody response in relation to COVID-19 severity Immunogenicity after two doses of inactivated virus vaccine in healthcare workers with and without previous COVID-19 infection: prospective observational study https://orcid.org/0000-0001-9387-2526Hande Arslan https://orcid.org/0000-0002-5708-7915